Eisai Clinical Trials

A Preliminary, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease.

E2020-A001-201

Study Overview

E2020
donepezil
Not available
Dec 1991 - Mar 1993
Alzheimer's disease
The primary efficacy endpoint was to evaluate the efficacy (primary efficacy parameters included ADAS-cog and CGIC) of three dose levels of E2020, versus Placebo, in patients with Alzheimer's  Disease.

  • Males and females (age 55 to 85 years)

  • Completed

  • Phase 2

  • United States

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Rogers S, Friedhoff LT, Apter JT, Richter RW, Hartford JT, Walshe TM, et al. The efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR